US 12,144,859 B2
B cell depleting agent for the treatment of atherosclerosis
Ziad Mallat, Paris (FR); Hafid Ait-Oufella, Paris (FR); Alain Tedgui, Paris (FR); and Thomas Tedder, Durham, NC (US)
Assigned to Institut National De La Santa Et De La Recherche Medicale (Inserm), Paris (FR); Duke University, Durham, NC (US); and Assistance Publique-Hôpitaux De Paris (APHP), Paris (FR)
Filed by Ziad Mallat, Paris (FR); Hafid Ait-Oufella, Paris (FR); Alain Tedgui, Paris (FR); and Thomas Tedder, Durham, NC (US)
Filed on Jun. 16, 2020, as Appl. No. 16/902,518.
Application 16/902,518 is a continuation of application No. 16/505,788, filed on Jul. 9, 2019, abandoned.
Application 16/505,788 is a continuation of application No. 13/790,771, filed on Mar. 8, 2013, abandoned.
Application 13/790,771 is a continuation of application No. 13/143,440, abandoned, previously published as PCT/EP2010/050048, filed on Jan. 5, 2010.
Claims priority of application No. 09290005 (EP), filed on Jan. 6, 2009; and application No. 09305013 (EP), filed on Jan. 7, 2009.
Prior Publication US 2020/0376118 A1, Dec. 3, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01)
CPC A61K 39/3955 (2013.01) [A61K 47/6849 (2017.08); C07K 16/244 (2013.01); C07K 16/2887 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01)] 10 Claims
 
1. A method for treating myocardial infarction by decreasing atherosclerotic plaque size in a subject in need thereof, consisting essentially of
administering a therapeutically effective amount of an anti-human CD20 antibody to said subject, wherein said anti-human CD20 antibody depletes or destroys mature B cells or interferes with B cell functions in said subject and increases fractional shortening, and wherein the therapeutically effective amount is sufficient to decrease atherosclerotic plaque size in the subject, and wherein the myocardial infarction is a ST segment elevation myocardial infarction, and wherein the administering step is performed at 1 hour after onset of the myocardial infarction.